Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Healthcare Disparities | 4 | 2021 | 169 | 1.020 |
Why?
|
| European Continental Ancestry Group | 8 | 2017 | 1166 | 0.870 |
Why?
|
| Colorectal Neoplasms | 4 | 2017 | 215 | 0.830 |
Why?
|
| Adenocarcinoma | 10 | 2016 | 308 | 0.820 |
Why?
|
| African Americans | 8 | 2017 | 1425 | 0.720 |
Why?
|
| Pancreatic Neoplasms | 7 | 2016 | 134 | 0.680 |
Why?
|
| Colonoscopy | 1 | 2017 | 46 | 0.570 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 447 | 0.550 |
Why?
|
| Transsexualism | 1 | 2016 | 3 | 0.540 |
Why?
|
| Minority Health | 1 | 2016 | 9 | 0.540 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 471 | 0.540 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 93 | 0.530 |
Why?
|
| Health Status Disparities | 2 | 2021 | 131 | 0.530 |
Why?
|
| Minority Groups | 1 | 2016 | 83 | 0.510 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 414 | 0.490 |
Why?
|
| Rural Health | 1 | 2014 | 44 | 0.480 |
Why?
|
| Biomedical Research | 1 | 2016 | 156 | 0.470 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 161 | 0.470 |
Why?
|
| Common Bile Duct Neoplasms | 4 | 2016 | 6 | 0.450 |
Why?
|
| Ampulla of Vater | 4 | 2016 | 6 | 0.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 101 | 0.450 |
Why?
|
| Middle Aged | 30 | 2021 | 11839 | 0.420 |
Why?
|
| Oxidative Stress | 1 | 2014 | 231 | 0.420 |
Why?
|
| Aged | 25 | 2021 | 10314 | 0.390 |
Why?
|
| Gallbladder Neoplasms | 3 | 2021 | 34 | 0.390 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2017 | 29 | 0.380 |
Why?
|
| Prostatectomy | 5 | 2020 | 83 | 0.380 |
Why?
|
| Appendiceal Neoplasms | 3 | 2017 | 98 | 0.370 |
Why?
|
| Male | 30 | 2021 | 19218 | 0.370 |
Why?
|
| Humans | 37 | 2021 | 32115 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 19 | 0.350 |
Why?
|
| Drug Industry | 1 | 2009 | 17 | 0.340 |
Why?
|
| Commerce | 1 | 2009 | 67 | 0.320 |
Why?
|
| Female | 25 | 2021 | 20016 | 0.320 |
Why?
|
| Biological Products | 1 | 2009 | 77 | 0.310 |
Why?
|
| Bile Duct Neoplasms | 2 | 2018 | 32 | 0.300 |
Why?
|
| Blood Transfusion | 2 | 2017 | 73 | 0.280 |
Why?
|
| Mutation | 3 | 2017 | 489 | 0.270 |
Why?
|
| Adult | 18 | 2018 | 9381 | 0.270 |
Why?
|
| Radiotherapy | 4 | 2020 | 82 | 0.260 |
Why?
|
| United States | 7 | 2021 | 3976 | 0.260 |
Why?
|
| Carcinoid Tumor | 2 | 2016 | 13 | 0.260 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 6 | 0.260 |
Why?
|
| Dermatology | 2 | 2018 | 163 | 0.250 |
Why?
|
| Neuroendocrine Tumors | 2 | 2015 | 18 | 0.250 |
Why?
|
| DNA, Mitochondrial | 2 | 2015 | 34 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 190 | 0.240 |
Why?
|
| Adenoma | 2 | 2015 | 35 | 0.230 |
Why?
|
| SEER Program | 4 | 2017 | 30 | 0.230 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 684 | 0.230 |
Why?
|
| Survival Rate | 9 | 2017 | 877 | 0.230 |
Why?
|
| Aged, 80 and over | 13 | 2018 | 3990 | 0.220 |
Why?
|
| Androgen Antagonists | 2 | 2020 | 19 | 0.210 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 753 | 0.210 |
Why?
|
| Brachytherapy | 2 | 2020 | 24 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 2265 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3510 | 0.190 |
Why?
|
| Cytodiagnosis | 2 | 2018 | 15 | 0.190 |
Why?
|
| Bile Ducts | 2 | 2018 | 20 | 0.180 |
Why?
|
| Treatment Outcome | 9 | 2021 | 3306 | 0.180 |
Why?
|
| Incidence | 3 | 2017 | 1199 | 0.170 |
Why?
|
| Prognosis | 7 | 2017 | 1497 | 0.160 |
Why?
|
| Registries | 2 | 2017 | 298 | 0.160 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 55 | 0.160 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 220 | 0.160 |
Why?
|
| Marital Status | 2 | 2016 | 23 | 0.150 |
Why?
|
| Air Ambulances | 1 | 2017 | 10 | 0.150 |
Why?
|
| Pathology | 1 | 2017 | 17 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2017 | 15 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2017 | 33 | 0.150 |
Why?
|
| Esophagectomy | 1 | 2017 | 15 | 0.150 |
Why?
|
| Risk Factors | 4 | 2021 | 3880 | 0.140 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 30 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 35 | 0.140 |
Why?
|
| Resuscitation | 1 | 2017 | 65 | 0.140 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 5 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 582 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2017 | 100 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 34 | 0.140 |
Why?
|
| Epithelial Cells | 1 | 2017 | 141 | 0.140 |
Why?
|
| Health Priorities | 1 | 2016 | 15 | 0.140 |
Why?
|
| Critical Care | 1 | 2017 | 106 | 0.130 |
Why?
|
| Medicare | 1 | 2017 | 206 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2016 | 76 | 0.130 |
Why?
|
| Survivors | 1 | 2017 | 163 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 154 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 81 | 0.130 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 4 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2016 | 120 | 0.130 |
Why?
|
| Vitamins | 1 | 2015 | 68 | 0.120 |
Why?
|
| Electrons | 1 | 2015 | 12 | 0.120 |
Why?
|
| Mitotic Index | 1 | 2014 | 2 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 195 | 0.120 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 30 | 0.120 |
Why?
|
| Georgia | 1 | 2014 | 14 | 0.120 |
Why?
|
| Isoprostanes | 1 | 2014 | 2 | 0.120 |
Why?
|
| beta Carotene | 1 | 2014 | 6 | 0.120 |
Why?
|
| Africa, Western | 1 | 2014 | 4 | 0.120 |
Why?
|
| Observer Variation | 3 | 2021 | 105 | 0.120 |
Why?
|
| Bone and Bones | 1 | 2015 | 94 | 0.120 |
Why?
|
| Carotenoids | 1 | 2014 | 10 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 192 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2014 | 35 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2015 | 107 | 0.120 |
Why?
|
| Medical Records | 1 | 2014 | 76 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2015 | 185 | 0.120 |
Why?
|
| Social Class | 1 | 2014 | 90 | 0.120 |
Why?
|
| Vitamin D | 1 | 2015 | 184 | 0.120 |
Why?
|
| Age Factors | 5 | 2017 | 1189 | 0.120 |
Why?
|
| Age Distribution | 1 | 2014 | 206 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2020 | 2284 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 111 | 0.110 |
Why?
|
| Calcium | 1 | 2015 | 307 | 0.110 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2012 | 2 | 0.110 |
Why?
|
| Gallbladder | 1 | 2012 | 3 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 408 | 0.110 |
Why?
|
| Polyps | 1 | 2012 | 8 | 0.110 |
Why?
|
| Comorbidity | 1 | 2014 | 566 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 214 | 0.100 |
Why?
|
| Diet | 1 | 2014 | 391 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 538 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 765 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 15 | 0.090 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.090 |
Why?
|
| Mucins | 3 | 2016 | 18 | 0.090 |
Why?
|
| Patents as Topic | 1 | 2009 | 2 | 0.090 |
Why?
|
| Drugs, Generic | 1 | 2009 | 15 | 0.090 |
Why?
|
| Neoplasms | 1 | 2017 | 728 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1542 | 0.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 166 | 0.090 |
Why?
|
| Young Adult | 4 | 2018 | 2666 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 876 | 0.080 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2020 | 12 | 0.080 |
Why?
|
| Disease Progression | 3 | 2017 | 594 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2009 | 177 | 0.080 |
Why?
|
| Urinary Incontinence | 2 | 2020 | 47 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2017 | 1817 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 137 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 560 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 317 | 0.060 |
Why?
|
| Logistic Models | 2 | 2017 | 783 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 483 | 0.060 |
Why?
|
| Allelic Imbalance | 1 | 2004 | 6 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2004 | 14 | 0.060 |
Why?
|
| Time Factors | 2 | 2021 | 2151 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2021 | 1429 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 367 | 0.050 |
Why?
|
| Chile | 1 | 2021 | 7 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 12 | 0.050 |
Why?
|
| Cause of Death | 1 | 2021 | 236 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 8 | 0.040 |
Why?
|
| Adolescent | 2 | 2017 | 3569 | 0.040 |
Why?
|
| Colectomy | 1 | 2017 | 24 | 0.040 |
Why?
|
| Appendectomy | 1 | 2017 | 16 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 16 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 39 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2017 | 13 | 0.040 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
| Clone Cells | 1 | 2017 | 36 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 18 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2017 | 23 | 0.040 |
Why?
|
| Genes, ras | 1 | 2017 | 26 | 0.040 |
Why?
|
| Military Medicine | 1 | 2017 | 24 | 0.040 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 32 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 62 | 0.040 |
Why?
|
| Abbreviated Injury Scale | 1 | 2017 | 57 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 82 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2017 | 113 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2017 | 82 | 0.040 |
Why?
|
| Emotions | 1 | 2017 | 58 | 0.040 |
Why?
|
| Urination | 1 | 2016 | 16 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 25 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 85 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 297 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 1062 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 43 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 99 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 148 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 472 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 322 | 0.030 |
Why?
|
| Anxiety | 1 | 2017 | 191 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 120 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2015 | 4 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 17 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 90 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 162 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 72 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2015 | 7 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2015 | 12 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 50 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 95 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 288 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 252 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 321 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 359 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 770 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 525 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 277 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 355 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 667 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 632 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 226 | 0.030 |
Why?
|
| Keratin-7 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Mucin-2 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Mucin-6 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Keratin-20 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Smoking | 1 | 2017 | 528 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 20 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 51 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 31 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2012 | 71 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 608 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 946 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 20 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 27 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 469 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2009 | 35 | 0.020 |
Why?
|
| Child | 1 | 2015 | 2442 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 765 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2004 | 7 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 198 | 0.010 |
Why?
|